# White House Drug Czar Clarifies That Marijuana Is ‘Still Illegal’ Following Trump … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/white-house-drug-czar-clarifies-that-marijuana-is-still-illegal-following-trump/ > **Published:** 2026-05-08T16:51:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:51-04:00 > **Clinical Summary:** Federal cannabis legal status remains complex. Review state law, liability coverage, and patient counseling strategies for 2025 enforcement uncertainty. --- ✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyHempTHC Why This Matters Clinicians need to understand that federal recriminalization of [hemp-derived THC](https://cedclinic.com/hemp-derived-thc-products-regulation-patient-access/) products creates legal ambiguity that affects patient counseling, prescribing practices, and documentation, particularly in states where cannabis remains legal. Patients using hemp THC products may face sudden legal consequences or supply disruptions, necessitating clinicians to discuss these risks and help patients understand the distinction between state and federal law regarding [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). This policy shift requires clinicians to stay informed about changing regulations that directly impact their ability to advise patients on legal product access and safety. Clinical Summary The White House Drug Czar has reiterated that marijuana remains federally illegal despite recent state-level legalization efforts, and federal enforcement actions are anticipated to target [hemp-derived THC](https://cedclinic.com/hemp-derived-thc-products-regulation-patient-access/) products later this year under existing legislation. This statement signals potential increased federal scrutiny of the cannabis market, including products marketed as “legal” hemp derivatives that contain THC, which have proliferated in states where cannabis remains prohibited or tightly regulated. For clinicians, this creates an uncertain legal environment that may complicate patient access to cannabis products, particularly in states relying on hemp-derived alternatives as a workaround to state prohibition. The anticipated recriminalization of hemp THC products could restrict the supply and availability of accessible cannabis options for patients currently using these products for symptom management. Physicians should counsel patients about the ongoing federal illegality of cannabis and hemp THC products, document this discussion in the medical record, and remain informed about changing enforcement priorities in their state and region. Clinicians should advise patients that federal legal status remains unchanged regardless of state laws, and that product availability and legality may shift substantially in coming months. Dr. Caplan’s Take “We’re about to see a significant disruption in [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) as federal enforcement tightens around hemp-derived THC products that patients have been using safely for years, and my concern isn’t theoretical—it’s about the patients sitting in my exam room who’ve found real symptom relief and now face uncertainty about access and legality.” Clinical Perspective The ongoing federal-state policy discord regarding cannabis legality creates substantial clinical ambiguity that warrants provider awareness. While some states have legalized cannabis for medical or recreational use, the federal government maintains it as a Schedule I controlled substance, and recent signals suggest potential enforcement shifts against hemp-derived THC products that currently proliferate in unregulated markets. This legal uncertainty complicates patient counseling, as providers may encounter patients using products of unknown potency and purity, yet cannot reliably predict how enforcement actions might affect product availability or patient access patterns. The distinction between federally illegal cannabis and state-legal products means clinicians should remain informed about their jurisdiction’s current regulations while maintaining evidence-based guidance on cannabis risks—particularly cognitive effects, dependence potential, and interactions with other medications—regardless of legal status. Practically, providers should document [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) consistently in medical records, clarify with patients the potency and source of products being used, and adjust 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20White%20House%20Drug%20Czar%20Clarifies%20That%20Marijuana%20Is%20%27Still%20Illegal%27%20Following%20Trump%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50854)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50854)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20White%20House%20Drug%20Czar%20Clarifies%20That%20Marijuana%20Is%20%27Still%20Illegal%27%20Following%20Trump%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D50854)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.marijuanamoment.net/white-house-drug-czar-clarifies-that-marijuana-is-still-illegal-following-trump-administrations-rescheduling-move/](https://www.marijuanamoment.net/white-house-drug-czar-clarifies-that-marijuana-is-still-illegal-following-trump-administrations-rescheduling-move/) Further Reading CED Clinic BlogClinical trial finds no difference in fluid treatment options for pediatric sepsis Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-placement-bromazolam-schedule-i/) Evidence Watch[Cannabis Use and Atrial Arrhythmias: Systematic Review & Meta-Analysis](https://cedclinic.com/cannabis-use-atrial-arrhythmias-risk-review/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).